share_log

Piper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $115

Benzinga ·  Mar 17 16:21  · Ratings

Piper Sandler analyst Allison Bratzel maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $140 to $115.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 321

Recommended

Write a comment